IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket: COSSARIZZA-1

In re Application of: Confirmation No: 5546

Andrea COSSARIZZA Group Art Unit: 1637

Serial No: 10/522,405 Examiner: Mark STAPLES

Filed: September 30, 2005 Washington, D.C.

For: METHOD OF DETERMINING THE COPY NUMBER OF A November 6, 2008

NUCLEOTIDE SEQUENCE

INFORMATION DISCLOSURE STATEMENT [IDS]

Honorable Commissioner for Patents U.S. Patent and Trademark Office Customer Service Window Randolph Building, Mail Stop Amendment 401 Dulany Street Alexandria, VA 22314

Sir:

This Information Disclosure Statement is submitted in accordance with 37 CFR §§1.97, 1.98, and it is requested that the information set forth in this statement and in the listed documents be considered during the pendency of the above-identified application, and any other application relying on the filing date of the above-identified application or cross-referencing it as a related application.

The cited NPL references are being made of record for purposes of discussion of §112 rejections, and are not believed to be relevant to patentability under § 102 or §103; moreover one reference has a publication date (2007) that is later than the present priority date (2002). The cited US patent document was disclosed in the specification as filed (at page 2, line 37), so it was known to the Examiner from the start of examination of this application.

[XX] 1. This IDS should be considered, in accordance with 37 CFR §1.97, as it is filed:

[] A. within three months of the filing date of the above-identified national application or within three months of the entry into the national stage of the above-identified international application.

[] B. before the mailing date of a first office action on the merits or before the mailing of a first Office action after the filing of a Request for Continued Examination under 37 CFR §1.114; or

[XX] C. after (A) and (B) above, but before final rejection or allowance, and Applicant has made the necessary certification (box "i" below) or paid the necessary fee (box "ii" below):

[]	i.	Counsel certifies that, upon information and belief, each item of
in	form	ation	listed herein either was

[] (a) first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS;

		[]	(b) not cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of undersigned after making reasonable inquiry, not known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this IDS.			
	[XX]	ii.	Credit Card Payment Form, PTO-2038, is attached authorizing			
payment of the fee set forth in 37 CFR §1.17(p), presently believed to be \$180.						
enclosed payment is incorrect, please charge any additional fees or credit any						
			at to Deposit Account No. 02-4035 of the undersigned.			
	over p.	ay mici	to beposit recount 110. 02 1055 of the undersigned.			
[]	D.	afte	r (A), (B) and (C) above, but before payment of the issue fee: Applicant			
states as follow	CFR §1.97(e) for consideration of this IDS, that, upon information and					
			ation listed herein either was			
,	[]	(a) fir	st cited in a communication from a foreign patent office in a counterpart foreign			
		applic	ation not more than three months prior to the filing of this IDS; or			

[XX] 2. In accordance with 37 CFR §1.98, this IDS includes a list (e.g., form BN/SB/08A/B) of all patents, publications, or other information submitted for consideration by the office, either incorporated into this IDS or as an attachment hereto. Other than U.S. patent(s) and/or published U.S. application(s), which 37 CFR §1.98(a)(2)(ii) does not require to be filed unless specifically required by the Office, a copy of each document listed is attached, except as explained below:

months prior to the filing of this IDS.

(b) not cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the undersigned after making reasonable inquiry, not known to any individual designated in 37 CFR §1.56(c) more than three

- [XX] 3. No explanation of relevance is necessary for documents in the English language (see reply to Comments 67 and 68 in the preamble to the final rules; 1135 OG 13 at 20).
- [XX] 4. In accordance with 37 CFR §§1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search has been made or that information cited is, or is considered to be, material to patentability as defined in 37 CFR §1.56(b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item and Applicant reserves the right to prove that the date of publication is in fact different.

Respectfully submitted, **BROWDY AND NEIMARK** Attorneys for Applicant(s)

By: /Shmuel Livnat/ Shmuel Livnat Registration No. 33,949

624 Ninth Street, N.W., Suite 300 Washington, D.C. 20001-5303 Telephone: (202)628-5197

Facsimile: (202)737-3528